Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Rapamycin (Sirolimus) for Autophagy Research
2026-09-24
Use Rapamycin (Sirolimus) as a controlled mTOR perturbation to test how growth signaling intersects with autophagy, survival, and viral latency in cancer models. A practical dose-and-time workflow helps separate target engagement from downstream effects—and avoids assuming rapamycin was tested in the featured EBV study.
FPH1 (BRD-6125) for Functional Hepatocyte Workflows
2026-09-24
FPH1 (BRD-6125) supports workflows that pair hepatocyte expansion with functional readouts, including albumin secretion, CYP3A4, and AFP. This guide shows how to build a controlled proliferation assay and how to interpret a separate light-regulated gene therapy study without confusing its findings with evidence for FPH1.
FPH1 (BRD-6125): Designing Functional Hepatocyte Assays
2026-09-23
FPH1 (BRD-6125) can support hepatocyte expansion, but cell growth alone does not establish a useful liver model. This guide explains how to pair proliferation measurements with functional readouts and interpret results alongside emerging light-regulated gene-expression research.
ERAD Hijacking for Transmembrane Protein Degradation
2026-09-23
Song and colleagues introduce ERAD-engaging chimeras (ERADECs), a targeted protein degradation platform that redirects transmembrane proteins to the ER E3 ligase SYVN1. Desonide-based ERADECs produced highly effective PD-L1 depletion, improved tumor suppression in vivo, and extended ERAD-mediated degradation to mutant huntingtin, offering a complementary route to lysosome- and proteasome-centered approaches.
Dronedarone (Multaq) Research Workflow
2026-09-22
Build exposure-aware electrophysiology workflows around Dronedarone (Multaq) for atrial fibrillation and atrial flutter research. The approach combines automated patch clamp, solvent control, and KCa2 channel benchmarking to distinguish clinically relevant pharmacology from high-concentration screening artifacts.
C34 and the Translational Logic of TLR4 Inhibition
2026-09-22
C34 provides a selective way to test whether TLR4-driven inflammation is causal across macrophage, enterocyte, and neuroinflammation models, while recent Taxus chinensis findings show how pharmacologic pathway control can strengthen translational interpretation.
VEGFC–Macrophage Signaling in NASH Fibrosis
2026-09-21
This 2026 Phytomedicine study identifies a hepatocyte VEGFC–VEGFR-3–macrophage regulatory axis that links metabolic liver injury to inflammatory cell recruitment and fibrosis. By combining a high-fat-diet mouse model, hepatocyte-specific Vegfc deletion, human cohort and transcriptomic data, and cell-based assays, the authors show how naringin and SAR131675 interrupt this pathway at complementary levels.
L-NMMA Acetate: Causal NOS Assay Design
2026-09-21
L-NMMA acetate is more than a nitric oxide synthase inhibitor: it is a causal perturbation tool for resolving NOS signaling pathway dependence. This article translates evidence from dental follicle cell research into practical assay-design and interpretation strategies.
Taxus chinensis Fruit, TLR4, and Neuroinflammation
2026-09-20
A Journal of Ethnopharmacology study reports that Taxus chinensis fruit extract improved aging-associated behavior and neuroinflammatory measures in a D-galactose mouse model. By combining behavioral testing, oxidative-stress profiling, BV2 microglial experiments, UPLC-MS/MS, and molecular docking, the work connects extract-level effects with the TLR4/NF-κB/NLRP3 axis while also identifying testable candidate compounds.
(-)-Blebbistatin in Cardiac Opto-Electrical Assays
2026-09-19
(-)-Blebbistatin can serve as more than a non-muscle myosin II inhibitor: it can help dissect mechanical confounding in cardiac optical and electrical measurements. This article connects its reversible actomyosin mechanism with the POEMS platform and provides a practical framework for interpreting electromechanical experiments.
SB 203580: Reliable p38 MAPK Assays
2026-09-18
Learn how SB 203580 (SKU A8254) can help laboratories distinguish p38 MAPK-dependent biology from nonspecific cytotoxicity while improving compound preparation and assay interpretation. This scenario-based guide covers viability, proliferation, cytotoxicity, formulation, controls, and vendor-selection decisions.
Dronedarone in AF Research: From Channels to Translation
2026-09-18
Dronedarone (Multaq) offers a valuable translational model for studying multi-channel antiarrhythmic pharmacology without assuming that every clinically relevant mechanism is represented by a single ion-channel target. This article connects KCa2.X evidence, assay design, compound handling, and strategic decision-making for atrial fibrillation and atrial flutter research.
Pregnenolone Carbonitrile: PXR Research Workflows
2026-09-17
Pregnenolone Carbonitrile is a practical rodent PXR probe for connecting xenobiotic-response signaling with cytochrome P450 CYP3A induction and hepatic fibrosis assays. This workflow-focused guide shows how to prepare PCN, design controls, interpret cardiac and hepatic readouts, and troubleshoot inconsistent activation without overstating translational relevance.
FH1 for iPS-Derived Hepatocyte Maturation
2026-09-17
FH1 helps turn iPS-derived hepatocyte-like cells into more functional models by improving albumin secretion, CYP3A4 expression, colony morphology, and AFP behavior. This practical guide connects FH1-based maturation workflows with controlled gene-expression assays while emphasizing dose optimization, analytical controls, and translational limitations.
p-tau Ser356, NUAK1, and Alzheimer’s Pathology
2026-09-16
The reference study establishes p-tau Ser356 as a pathology-associated tau species that rises with Alzheimer’s disease progression and is frequently present in neurofibrillary tangles and synaptic compartments. Its brain-slice experiments further show that NUAK inhibition has model-dependent effects, lowering p-tau Ser356 specifically in live human tissue but producing broader tau and neuronal-protein losses in mouse cultures.